NCT07020156View on ClinicalTrials.gov

A First-in-Human Phase I Trial of OX118 in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

October 29, 2025

Study Completion Date

October 29, 2025

Conditions

Immune System

Interventions

DRUG

OX118 or placebo

OX118 is a human monoclonal antibody targeting OX40 ligand (OX40L).

Trial Locations (1)

75185

RECRUITING

CTC, Clinical Trial Consultants AB, Uppsala

Sponsors

Lead Sponsor

Oxion Biologics AB

All Listed Sponsors

lead

Oxion Biologics AB

INDUSTRY

NCT07020156 - A First-in-Human Phase I Trial of OX118 in Healthy Volunteers | Biotech Hunter | Biotech Hunter